(Q38099408)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

meta-analysis

0 references

title

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Emilio J Alegre-Del-Rey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

R Castaño-Lara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

F Puigventós-Latorre

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

J M Borrero-Rubio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

J F López-Vallejo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

17 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Pharmacy and Therapeutics

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

286-293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJCPT.12045

21 January 2018

Identifiers

DOI

10.1111/JCPT.12045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23590560%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference